Guwahati Mail

Arteriotomy Closure Devices – Market Insight, Competitive Landscape, and Market Forecast – 2030

DelveInsight’s comprehensive report, “Arteriotomy Closure Devices – Market Insight, Competitive Landscape, and Market Forecast – 2030” provides comprehensive insights into the arteriotomy closure devices competitive landscape, including historical and forecasted market trends, and comprehensive regional analysis across North America, Europe, Asia-Pacific, and the Rest of the World.

Download the Arteriotomy Closure Devices Market Forecast Report to understand which factors are driving the Arteriotomy Closure Devices therapeutic market @ Arteriotomy Closure Devices Market Trends.

Arteriotomy closure devices represent a crucial advancement in cardiovascular procedural care, designed to seal arterial puncture sites following angiography, percutaneous coronary intervention, or peripheral interventions. These devices facilitate faster hemostasis, reduce the risk of vascular complications, and significantly decrease patient recovery time compared to traditional manual compression methods. Since their introduction in 1995, ACDs have revolutionized post-procedural care by enabling quicker ambulation and improved patient comfort while maintaining high safety standards.

The expanding prevalence of cardiovascular diseases globally continues to fuel market growth, with an estimated 640K PCI procedures performed in the US alone in 2017. In Europe, the rate of percutaneous coronary interventions varies significantly by country, with Germany reporting the highest number of procedures in 2020, highlighting the substantial procedural volume driving the arteriotomy closure devices market. The rise in these coronary interventions directly correlates with increased demand for effective and efficient arterial closure solutions.

DelveInsight’s analysis segments the arteriotomy closure devices market by product type (active closure devices and passive closure devices), application (femoral arterial access procedures and radial arterial access procedures), and end-user (hospitals, ambulatory care centers, and others). Active closure devices, which include suture-based devices, staple-based devices, and vascular closure devices utilizing collagen plugs or hemostatic agents, currently hold the largest market share and are expected to maintain their dominance throughout the forecast period.

The competitive landscape features several key players driving innovation in this space. Abbott Laboratories, Medtronic PLC, Arstatis, Teleflex Incorporated, Cardinal Health, Terumo Corporation, St. Jude Medical, Morris Innovative Research, Scion BioMedical, and Merit Medical Systems lead the market with their comprehensive portfolios of closure solutions. Other significant competitors include Haemonetics Corporation (which acquired Cardiva Medical), Otsuka Medical Devices (Veryan Medical), and Vivasure Medical. These companies continue to focus on technological advancements and expanding their global footprint to capitalize on growing market opportunities.

Download the Arteriotomy Closure Devices Competitive Landscape Report for in-depth Arteriotomy Closure Devices competitive insights.

Recent innovations demonstrate the industry’s commitment to addressing unmet needs. In March 2025, Vasorum USA, Inc. received FDA approval for the Celt ACD Plus system, a next-generation small-bore arterial closure device. The Celt ACD Plus features blood signal technology for visual placement feedback, aiming to reduce complications and shorten the learning curve for health professionals.

Additionally, in June 2024, Haemonetics Corporation expanded its VASCADE portfolio with the launch of the VASCADE MVP XL mid-bore venous closure device, engineered specifically for larger sheaths used in procedures like cryoablation. This device incorporates 58% more collagen and a larger collapsible disc to achieve more rapid hemostasis, showcasing the ongoing evolution toward specialized solutions for various procedural contexts.

Furthermore, in October 2024, Vivasure Medical’s PerQseal system, a sutureless and fully-absorbable closure device for large-bore arterial access, showed initial positive results from the US IDE PATCH pivotal study presented at TCT 2024.

Discover evolving trends in the Arteriotomy Closure Devices treatment landscape @ Arteriotomy Closure Devices Recent Developments.

The adoption of arteriotomy closure devices is increasingly influenced by the ongoing shift toward radial access approaches for coronary interventions. According to a study published in August 2022, 24% of patients undergoing chronic total occlusion PCI had radial-only access, which showed lower rates of access site complications compared to femoral access, while maintaining similar technical success rates. This growing preference for radial access is reshaping procedural workflows and device selection considerations.

Looking ahead, the arteriotomy closure devices market is expected to benefit from several emerging trends, including the growing adoption of bioresorbable materials, integration of automated technologies into closure procedures, and continued innovations targeted at large arterial punctures. The expanding healthcare infrastructure in emerging economies, coupled with increasing focus on patient safety and comfort, will further drive market growth through 2030.

Table of Contents

1. Arteriotomy Closure Devices Market Report Introduction

2. Arteriotomy Closure Devices Market Executive Summary

3. Regulatory and Patent Analysis

4. Arteriotomy Closure Devices Market Key Factors Analysis

5. Arteriotomy Closure Devices Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Arteriotomy Closure Devices Market

7. Arteriotomy Closure Devices Market Layout

8. Arteriotomy Closure Devices Global Company Share Analysis

9. Arteriotomy Closure Devices Company and Product Profiles

10. PROJECT APPROACH

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services